Abstract:Background & aims: Macrophages contribute to liver disease, but their role in cholestatic liver injury, including primary sclerosing cholangitis (PSC), is unclear. We tested the hypothesis that macrophages contribute to the pathogenesis of, and are therapeutic targets for, PSC. Methods: Immune cell profile, hepatic macrophage number, localization and polarization, fibrosis, and serum markers of liver injury and cholestasis were measured in an acute (intrabiliary injection of the inhibitor of apoptosis antagonist BV6) and chronic (Mdr2-/- mice) mouse model of sclerosing cholangitis (SC). Selected observations were confirmed in liver specimens from patients with PSC. Because of the known role of the CCR2/CCL2 axis in monocyte/macrophage chemotaxis, therapeutic effects of the CCR2/5 antagonist cenicriviroc (CVC), or genetic deletion of CCR2 (Ccr2-/- mice) were determined in BV6-injected mice. Results: We found increased peribiliary pro-inflammatory (M1-like) and alternatively-activated (M2-like) monocyte-derived macrophages in PSC compared to normal livers. In both SC models, genetic profiling of liver immune cells identified a predominance of monocytes/macrophages; immunohistochemistry confirmed peribiliary monocyte-derived macrophage recruitment (M1>M2-polarized), which paralleled injury onset and was reversed upon resolution in acute SC mice. PSC, senescent and BV6-treated human cholangiocytes released monocyte chemoattractants (CCL2, IL-8) and macrophage-activating factors in vitro. Pharmacological inhibition of monocyte recruitment by CVC treatment or CCR2 genetic deletion attenuated macrophage accumulation, liver injury and fibrosis in acute SC. Conclusions: Peribiliary recruited macrophages are a feature of both PSC and acute and chronic murine SC models. Pharmacologic and genetic inhibition of peribiliary macrophage recruitment decreases liver injury and fibrosis in mouse SC. These observations suggest monocyte-derived macrophages contribute to the development of SC in mice and in PSC pathogenesis, and support their potential as a therapeutic target. Lay summary: Primary sclerosing cholangitis (PSC) is an inflammatory liver disease which often progresses to liver failure. The cause of the disease is unclear and therapeutic options are limited. Therefore, we explored the role of white blood cells termed macrophages in PSC given their frequent contribution to other human inflammatory diseases. Our results implicate macrophages in PSC and PSC-like diseases in mice. More importantly, we found that pharmacologic inhibition of macrophage recruitment to the liver reduces PSC-like liver injury in the mouse. These exciting observations highlight potential new strategies to treat PSC.

Elevated CD169 expressing monocyte/macrophage promotes systemic inflammation and disease progression in cirrhosis

Increase of Infiltrating Monocytes in the Livers of Patients with Chronic Liver Diseases

Altered Peripheral Blood Monocyte Phenotype and Function in Chronic Liver Disease: Implications for Hepatic Recruitment and Systemic Inflammation

Monocyte Chemoattractant Protein 1 Released from Macrophages Induced by Hepatitis C Virus Promotes Monocytes Migration

Genetic Landscape and Immune Mechanism of Monocytes Associated with the Progression of Acute-on-chronic Liver Failure

Unraveling the Heterogeneity of CD8+ T-Cell Subsets in Liver Cirrhosis: Implications for Disease Progression

Liver Myofibroblasts Regulate the Phenotype and Function of Monocytes Through Soluble Factors in Cirrhosis.

The functional characteristics CCNI modulation of myeloid- derived suppressor cells in liver inflammation.

A functional characteristic of cysteine-rich protein 61: modulation of myeloid-derived suppressor cells in liver inflammation

Characteristic Gene Expression in the Liver Monocyte-Macrophage-dc System is Associated with the Progression of Fibrosis in NASH.

CD11b+CD43hiLy6Clo splenocyte‐derived macrophages exacerbate liver fibrosis via spleen‐liver axis

Monocyte-derived macrophages contribute to the deterioration of immunological liver injury in mice

Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression

The significance of CD14+ monocytes in peripheral blood stem cells for the treatment of rat liver cirrhosis

Activated Hepatic Stellate Cells Induce Infiltration and Formation of CD163+ Macrophages via CCL2/CCR2 Pathway

Liver myofibroblasts up-regulate monocyte CD163 expression via PGE2 during hepatitis B induced liver failure

Macrophages contribute to the pathogenesis of sclerosing cholangitis in mice

Availability of an inflammatory macrophage niche drives phenotypic and functional alterations in Kupffer cells

Decreased Tim-3 expression is associated with functional abnormalities of monocytes in decompensated cirrhosis without overt bacterial infection.

microRNA associated with hepatocyte injury and systemic inflammation may predict adverse outcomes in cirrhotic patients

Dysregulation of innate cell types in the hepatic immune microenvironment of alcoholic liver cirrhosis